Davis KL, Lenz C, Houghton K, Kaye JA. Clinical outcomes of crizotinib in real-world practice settings for patients with advanced ALK-positive non-small cell lung cancer. Poster presented at the Multidisciplinary Thoracic Cancers Symposium; March 2017. San Francisco, CA. [abstract] Int J Radiat Oncol Biol Phys. 2017 May 1; 98(1):238-9.
Davis KL, Lenz C, Houghton K, Kaye JA. Real-world clinical outcomes of crizotinib treatment in ALK-positive non-small cell lung cancer patients with brain metastases. Poster presented at the Multidisciplinary Thoracic Cancers Symposium; March 2017. San Francisco, CA. [abstract] Int J Radiat Oncol Biol Phys. 2017 May 1; 98(1):239.
VanderWalde NA, Meyer AM, Deal AM, Layton JB, Liu H, Carpenter WR, Weissler MC, Hayes DN, Fleming ME, Chera BS. Effectiveness of chemoradiation for head and neck cancer in an older patient population. Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):30-7. doi: 10.1016/j.ijrobp.2014.01.053
Smith VK, Evans MF, Banzhaf HS, Poulos C. Can weak substitution be rehabilitated? Environ Resour Econ (Dordr). 2010 Feb 1;45(2):203-21.
Heyes A. Clinical trial experience with Functional Assessment of Cancer Therapy—Lung in conventional and targeted non—small cell lung cancer therapy. Semin Oncol. 2004 Jun 1;31(Suppl. 9):16-22.
Williams AG, Dhamrait SS, Wootton PT, Day SH, Hawe E, Payne JR, Myerson SG, World M, Budgett R, Humphries SE, Montgomery HE. Bradykinin receptor gene variant and human physical performance. J Appl Physiol. 2004;96(3):938-42.
Mansfield CA. Despairing over disparities: an empirical analysis of the relationship between willingness-to-pay and willingness-to-accept. Environ Resour Econ (Dordr). 1999;13(2):219-34.